A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis

New England Journal of Medicine

Volumn 334, Issue 17, 1996, Pages 1090-1094

  Weiss, Ethan J ^a   Bray, Paul F ^a   Tayback, Matthew ^b   Schulman, Steven P ^a   Kickler, Thomas S ^a   Becker, Lewis C ^a   Weiss, James L ^a   Gerstenblith, Gary ^a   Goldschmidt Clermont, Pascal J ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOGEN; FIBRINOGEN RECEPTOR; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY THROMBOSIS; DOT HYBRIDIZATION; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; UNSTABLE ANGINA PECTORIS;

ACUTE DISEASE; ANGINA, UNSTABLE; CASE-CONTROL STUDIES; CORONARY THROMBOSIS; FEMALE; GENOTYPE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; POLYMORPHISM, GENETIC; RISK FACTORS;

EID: 0029875770     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199604253341703     Document Type: Article

References (41)

1. Chandler AB, Chapman I, Erhardt LR, et al. Coronary thrombosis in myocardial infarction: report of a workshop on the role of coronary thrombosis in the pathogenesis of acute myocardial infarction. Am J Cardiol 1974;34 823-33.
2. Lam JYT, Chesebro JH, Steele PM, Dewanjee MK, Badimon L, Fuster V. Deep arterial injury during experimental angioplasty, relation to a positive indium-111-labeled platelet scintigram, quantitative platelet deposition and mural thrombosis J Am Coll Cardiol 1986;8:1380-6.
3. Fitzgerald DJ, Roy L, Catella F, FitzGerald GA. Platelet activation in unstable coronary artery disease. N Engl J Med 1986;315:983-9.
4. Davies MJ. A macro and micro view of coronary vascular insult in ischemic heart disease. Circulation 1990;82:Suppl:II-38-II-46.
5. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992; 326:242-50.
6. Jang Y, Lincoff AM, Plow ER Topol EJ. Cell adhesion molecules in coronary artery disease. J Am Coll Cardiol 1994;24:1591-601
7. DeWood MA, Stifter WF, Simpson CS, et al Coronary arteriographic findings soon after non-Q-wave myocardial infarction. N Engl J Med 1986;315: 417-23.
8. Plow EF, Ginsberg MH. Cellular adhesion: GPIIb-IIIa as a prototypic adhesion receptor. Prog Hemost Thromb 1989,9:117-56.
9. Coller BS Platelets and thrombolytic therapy. N Engl J Med 1990;322:33-42.
10. Lewis HD Jr, Davis JW, Archibald DG, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina, results of a Veterans Administration Cooperative study. N Engl J Med 1983; 309.396-403.
11. Cairns JA, Gent M, Singer J, et al. Aspirin, sulfinpyrazone, or both in unstable angina: results of a Canadian Multicenter Trial. N Engl J Med 1985;313: 1369-75
12. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2 Lancet 1988;2 349-60
13. Ridker PM, Manson JE, Buring JE, Muller JE, Hennekens CH. Circadian variation of acute myocardial infarction and the effect of low-dose aspirin in a randomized trial of physicians. Circulation 1990;82:897-902.
14. Ridker PM, Manson JE, Gaziano JM, Buring JE, Hennekens CH Low-dose aspirin therapy for chronic stable angina: a randomized, placebo-controlled clinical trial. Ann Intern Med 1991;114:835-9.
15. Ridker PM, Manson JE, Buring JE, Goldhaber SZ, Hennekens CH. Clinical characteristics of nonfatal myocardial infarction among individuals on prophylactic low-dose aspirin therapy. Circulation 1991;84:708-11.
16. Verheut FW, van der Laarse A, Funke-Kupper AJ, Sterkman LG, Galema TW, Roos JP. Effects of early intervention with low-dose aspirin (100 mg) on infarct size, reinfarction and mortality in anterior wall acute myocardial infarction. Am J Cardiol 1990;66:267-70.
17. The RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 1990;336.827-30.
18. Nyman I, Larsson H, Wallentin L. Prevention of serious cardiac events by low-dose aspirin in patients with silent myocardial ischemia: the Research Group on Instability in Coronary Artery Disease in Southeast Sweden. Lancet 1992;340:497-501.
19. Juul-Moller S, Edvardsson N, Jahnmatz B, Rosen A, Sorenson S, Omblus R Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris: the Swedish Angina Pectoris Aspirin Trial (SAPAT) Group. Lancet 1992;340:1421-5.
20. Hoffman W, Forster W Two year Cottbus reinfarction study with 30 mg aspirin per day. Prostaglandins Leukol Essent Fatty Acids 1991;44:159-69.
21. The Persamine Aspirin Reinfarction Study Research Group. Persantine and aspirin in coronary heart disease. Circulation 1980;62:449-61.
22. Klimt CR, Knatterud GL, Stamler J, Meier P Persantine-Aspirin Reinfarction Study. II. Secondary coronary prevention with persantine and aspirin J Am Coll Cardiol 1986,7:251-69.
23. 2 fragments of murine monoclonal antibody 7E3 directed against human platelet glycoprotein IIb/IIIa in patients with unstable angina pectoris. J Clin Invest 1990;86:651-9.
24. Coller BS. Blockade of platelet GPIIb/IIIa receptors as an antithrombotic strategy. Circulation 1995;92:2373-80
25. 2 antibody directed against the platelet GPIIb/IIIa receptor complex prevents coronary artery thrombosis in the canine heart. J Mol Cell Cardiol 1989; 21:393-405.
26. The EPIC Investigators Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956-61
27. Trip MD, Cats VM, van Capelle FJL, Vreeken J. Platelet hyperreactivity and prognosis in survivors of myocardial infarction N Engl J Med 1990; 322 1549-54.
28. Newman PJ, McFarland JG, Aster RH. Alloimmune thrombocytopenias In: Loscalzo J, Schafer AI, eds. Thrombosis and hemorrhage Boston: Blackwell Scientific, 1994:529-43.
29. Kickler TS. Platelet immunology. In: Anderson KC, Ness PM, eds. Scientific basis of transfusion medicine, implications for clinical practice Philadelphia W.B. Saunders, 1994:304-15.
30. Shulman NR, Aster RH, Leitner A, Hiller MC. Immunoreactions involving platelets. V. Post-transfusion purpura due to a complement-fixing antibody against a genetically controlled platelet antigen: a proposed mechanism for thrombocytopenia and its relevance in "autoimmunity." J Clin Invest 1961, 40:1597-620
31. van Loghem JJ Jr, Dorfmeijer H, van der Hart M, Schreuder F. Serological and genetieal studies on a platelet antigen (Zw). Vox Sang 1959;4:161-9.
32. A1. Mol Immunol 1979;16:353-60.
33. 33 amino acid polymorphism in membrane glycoprotein IIIa, and are distinguishable by DNA typing J Clin Invest 1989;83:1778-81.
34. Kim HO, Jin Y, Kickler TS, Blakemore K, Kwon OH, Bray PF. Gene frequencies of the five major human platelet antigens in African American, white, and Korean populations. Transfusion 1995;35:863-7
35. A2 Tissue Antigens 1995,46.374-81.
36. A1 in blacks Transfusion 1986;26 531-2.
37. Bray PF, Jin Y, Kickler T. Rapid genotyping of the five major platelet alloantigens by reverse dot-blot hybridization Blood 1994;84.4361-7.
38. Zimrin AB, Gidwitz S, Lord S, et al The genomic organization of platelet glycoprotein IIIa. J Biol Chem 1990;265:8590-5
39. Jin Y, Dietz HC, Nurden A, Bray PF Single-strand conformation polymorphism analysis is a rapid and effective method for the identification of mutations and polymorphisms in the gene for glycoprotein IIIa Blood 1993, 82:2281-8.
40. von dem Borne AEG, Decary F Nomenclature of platelet-specific antigens. Transfusion 1990;30:477
41. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995;332:1553-9.